
© 2024 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
428,60 | 429,50 | 04.04. | |
429,70 | 431,00 | 04.04. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks | ||
Fr | Tariffs To Impact End Demand: Goldman Sachs Analyst Expects Drag On Corporate Spending, Hiring | ||
Fr | Iron Ore Set To Slide Further As Trump Tariffs, China Slowdown Collide, Goldman Says | ||
Fr | Goldman Sachs Lowers Warner Bros Discovery Q1 Estimates Amid Streaming Challenges | ||
Fr | U.S. Oil Price Skids To 4-Year Low; Goldman Slashes Oil Outlook |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | Lantheus bolsters radiopharmaceutical portfolio with acquisition | ||
Di | Lantheus Holdings, Inc. - 8-K, Current Report | ||
Di | Lantheus stärkt Radiopharmaka-Portfolio durch Übernahme | ||
Di | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Evergreen Theragnostics | BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
07.03. | Lantheus Holdings-Präsident Paul Blanchfield verkauft Aktien im Wert von 204.232 US-Dollar |
Unternehmen / Aktien | Kurs | % |
---|---|---|
GOLDMAN SACHS GROUP INC | 428,95 | -0,27 % |
LANTHEUS HOLDINGS INC | 82,70 | -0,36 % |